Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis
Applied Health Economics and Health Policy · 2023
DOI: 10.1007/s40258-022-00784-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, 2023. Verfasst von Yawen Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis, Postmenopausal, Osteoporotic Fractures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: This study evaluated the cost effectiveness of denosumab versus alendronate for secondary prevention of osteoporotic fractures among post-menopausal women in China. METHODS: A validated individual-level simulation model of osteoporotic fractures in the Chinese setting was adapted. Allowing both treatment discontinuation and waning effects, the analysis aimed to evaluate the incremental cost-effectiveness ratio of denosumab compared to alendronate by simulating a cohort of previously fractured individuals over the residual lifetime from the healthcare system perspective. Hip, vertebral, and wrist/humeral fractures were tracked along with the associated medical costs and quality-adjusted life-years. Age-related health state utility values, health state utility values of fractures, costs, fracture incidence, and mortality risks for Chinese were used whenever available. Comparative effectiveness data were obtained from a published network meta-analysis. One-way and probabilistic sensitivity analyses were conducted. RESULTS: In the base case, denosumab was dominated by alendronate with incremental costs of CN¥2743 (US$425) and incremental health outcomes of - 0.20 quality-adjusted life-years at its current price in mainland China. It remained dominated in all one-way sensitivity analysis robustness checks. However, denosumab was cost effective if both drugs did not carry any waning effects. In the probabilistic sensitivity analysis, denosumab remained dominated in all replications. CONCLUSIONS: Denosumab is not cost effective for preventing secondary fractures among overall postmenopausal women in China. It is advisable to identify alternative denosumab regimens for high-risk subgroups among previously fractured postmenopausal women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China.
- School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
- School of Health Sciences, Western Sydney University, Campbelltown, NSW, Australia. l.si@westernsydney.edu.au.
- School of Health Policy & Management, Nanjing Medical University, Nanjing, Jiangsu, China. l.si@westernsydney.edu.au.
- , Locked Bag 1797, Penrith, NSW, 2751, Australia. l.si@westernsydney.edu.au.
ORCID-Profile: Yawen Jiang, Lei Si
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Jiang, Y., Jiang, S., Li, L., Shi, S., Li, M., & Si, L. (2023). Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-022-00784-3
Vancouver
Jiang Y, Jiang S, Li L, Shi S, Li M, Si L. Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis. Applied Health Economics and Health Policy. 2023. doi:10.1007/s40258-022-00784-3
BibTeX
@article{Jiang2023,
author = {Jiang, Yawen and Jiang, Shan and Li, Limin and Shi, Si and Li, Mincai and Si, Lei},
title = {Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis},
journal = {Applied Health Economics and Health Policy},
year = {2023},
doi = {10.1007/s40258-022-00784-3}
}
EUVIMED